Risk alert: FDA relabels intragastric balloon systems due to possible related deaths

June 4, 2018 Wayne Wenske

In collaboration with manufacturers Apollo Endosurgery and ReShape LifeSciences, the FDA has approved new labeling for the Orbera and ReShape balloon systems to include more information about possible deaths associated with the use of these devices.

Both of these systems consist of liquid-filled balloons used as weight loss devices to treat obesity.

The FDA is recommending that health care providers:

instruct patients regarding symptoms of potentially life-threatening complications such as balloon deflation, gastrointestinal obstruction, ulceration, and gastric and esophageal perforation; and
monitor patients closely during treatment with these systems for potential complications, including acute pancreatitis and spontaneous hyperinflation.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program. Instructions are found on the FDA website.

About the Author

Wayne Wenske is Senior Marketing Coordinator at Texas Medical Liability Trust. He can be reached at wayne-wenske@tmlt.org.
More Content by Wayne Wenske

Suicide awareness and prevention

Recent events and reports offer a reminder that effective suicide prevention resources are available to the...

Risk alert: Birth control pills recalled

Allergan recalls sample packs of Taytulla birth control pills

Risk alert: FDA relabels intragastric balloon systems due to possible related deaths

About the Author

Previous Article

Next Article

Risk alert: FDA relabels intragastric balloon systems due to possible related deaths

About the Author

Previous Article

Next Article

Most Recent Articles

With the growing popularity of medical spas comes an increased risk of malpractice lawsuits for physicians who offer medical spa services within their practices.

Approximately 100 million people in the U.S. had their personal information obtained by a software engineer who gained unauthorized access to Capital One credit card applications and customer data.

Allergan announced that they are recalling Biocell textured breast implants from the global market.

TMLT CEO Robert Donohoe on TMLT's 40th anniversary.

New legislation places a 10-day limit on opioid prescriptions for acute pain.

The requirement for Texas physicians to check the Texas Prescription Monitoring Program before prescribing certain controlled substances has been delayed until March 20.

In Texas, health care liability claims have their own statutes of limitations and how these laws are applied can be tricky.

This article explores the topic of suicide, particularly risk management considerations and legal implications for physicians and health care providers treating potentially suicidal patients.

An ob-gyn based in Austin, Texas, discusses her work to increase awareness of human trafficking in health care settings.

Physicians received a fraudulent questionnaire asking for confidential information.

More on the FDA's announcement to halt sales of transvaginal mesh products

Dr. Milman co-teaches TMLT’s 2019 summer CME seminar series in San Antonio and Forth Worth.

From a legal and liability perspective, a “medical director” is a physician who serves in an administrative capacity as head of an organized medical staff

Learn about employment and human resources issues through the EPLI Pro website.

If you experienced a HIPAA breach that affected fewer than 500 individuals in 2018, the deadline to report that breach to HHS is March 1.

HHS released voluntary cyber security practices to the health care industry with the aim of providing practice guidelines to reduce cyber security risks.

Texas physicians will be required to use new schedule II prescription forms beginning June 1, 2019.

A company by any other name is not the same.

As smartphones, tablets, and other portable devices become commonplace in health care, the risk for mistakes increases.

Ransomware is a form of cyber extortion — and a serious business risk. Also considered "electronic vandalism," ransomware can corrupt or destroy your data.